Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Calliditas Therapeutics AB
Calliditas Therapeutics AB
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
AbbVie and Gedeon Richter join forces to advance neuropsychiatric target R&D
The companies will aim to discover and progress targets for neuropsychiatric disorders
Containment in a high potent manufacturing facility
Throughout the pharmaceutical industry, there is a lack of consistency regarding the assignment of Occupational Exposure Limits (OELs) to specific bands
Rousselot
Rousselot is the global leader* of collagen-based solutions for the food, health and nutrition, biomedical and pharmaceutical sectors. Working in partnership with our global...
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Causes and solutions for dark spots in tablet manufacturing
Natoli Engineering examines the causes and solutions for dark spots that can halt production
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon
China's National Medical Products Administration (NMPA) has approved Nefecon for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression
Regulatory
EMA issues positive opinion on Calliditas' orphan drug
Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients
Full details from Calliditas Therapeutics’ Phase 3 study released
Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Drug Delivery
Chinese NMPA accepts Calliditas' partner Everest Medicines NDA
Chronic kidney disease is one of the most serious public health problems in China, where IgAN is estimated by Everest to affect around five million people
Calliditas budesonide therapy approved to reduce proteinuria
Proteinuria is associated with IgAN, however it has not yet been established whether the therapy slows kidney function decline in patients with the condition
Regulatory
Calliditas receives fast track FDA designation for PBC candidate
The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing
Calliditas and Everest Medicines enter $120m development deal in China
The agreement gives Everest Medicines exclusive rights to develop and commercialise Nefecon in five countries in East Asia
Subscribe now